紫杉醇联合FUDR治疗晚期胃癌的临床观察

为了观察紫杉醇(PTX)联合脱氧氟尿苷(FUDR)/亚叶酸钙(CF)方案治疗晚期胃癌近期疗效及其不良反应,将58例晚期胃癌患者,采用PTX135mg/m2,静脉滴入3h,d1,CF100mg/m2,静脉滴入2h,d1～d5,FUDR425mg/m2,静脉滴入2h,d1,再续滴入FUDR350mg/(m2.d),微量化疗泵24h持续滴入(civ)d1～d5,21d为1个周期,至少完成2个周期。58例晚期胃癌患者,CR3例(5.2%),PR30例(51.7%),SD13例(22.4%),PD12例(20.7%),总有效率(CR PR)达56.9%。主要不良反应为骨髓抑制、脱发和肌肉酸痛,无化疗相关死亡。初步研究结果提示,PTX联合FUDR/CF方案一线治疗晚期胃癌具有较好的疗效和安全性。

Clinical study of paclitaxel combined with doxifluridine in treatment of advanced gastric carcinoma

The objective of this study was to observe the therapentic effects and toxicity of paclitaxel (PTX), Doxifluridine (FUDR) and calcium (CF) folinate combination chemothraphy on advanced gastric carcinoma. Fifty-eight patients with advanced gastric carcinoma received PTX 135 mg/m2 d1, continuous injection (CI) for 3 hours, CF 100 mg/m2 d1-d5,CI for 2 hours and FUDR 425 mg/m2 d1 CI for 2 hours, then FUDR 350 mg/m2 using an ambulatory pump continuous infusion from the first to fifth day, and one cycle consisted of 21 days. The overall response rate was 56.9%, including CR three cases (5.2%), PR thirty cases (51.7%). The main side effects were marrow suppression, alopecia and musculoskeletal pain. In conclusion, PTX, FUDR and CF combination chemotherapy regimen is effective in the treatment of advanced gastric carcinoma. The toxicity is liable to be well tolorated.